1.1.1.100	(E)-1-(4-methylpiperidin-1-yl)-3-phenylprop-2-en-1-one	80% residual activity	155193	
1.1.1.100	(E)-2-nitrophenyl cinnamate	-	77139	
1.1.1.100	(E)-3-phenoxybenzyl 3-(benzo[d][1,3]dioxol-5-yl)acrylate	61% residual activity	155191	
1.1.1.100	(E)-4-cyanophenyl 3-(benzo[d][1,3]dioxol-5-yl)acrylate	-	77138	
1.1.1.100	(E)-benzyl 3-(benzo[d][1,3]dioxol-5-yl)acrylate	71% residual activity	155192	
1.1.1.100	(E)-phenyl 3-(benzo[d][1,3]dioxol-5-yl)acrylate	69% residual activity	77137	
1.1.1.100	1,2,3,4,6-penta-O-galloyl-beta-D-glucose	mixed type of inhibition. IC50 value 0.9 microgramm per ml, Ki value 0.21 microgramm per ml	12736	
1.1.1.100	1,2,3,4,6-penta-O-galloyl-beta-D-glucose	minimal inhibitory concentration 0.125 mg/ml	12736	
1.1.1.100	1,2,3,4,6-penta-O-galloyl-beta-D-glucose	minimal inhibitory concentration 0.25 mg/ml	12736	
1.1.1.100	1,2,3,4,6-penta-O-galloyl-beta-D-glucose	compound is transported across cancer cell membrane to further down-regulate FAS and activate caspase-3 in MDA-MB-231 cells. Compared with other FAS inhibitors, including catechin gallate and morin, 1,2,3,4,6-penta-O-galloyl-beta-D-glucose involves a higher reversible fast-binding inhibition with an irreversible slow-binding inhibition, i.e. saturation kinetics with a dissociation constant of 0.59 microM and a limiting rate constant of 0.16 per min. The major reacting site of PGG is on the beta-ketoacyl reduction domain of FAS. Compound exhibits different types of inhibitions against the three substrates in the FAS overall reaction	12736